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Acute Leukemia in Association With Langerhans Cell Histiocytosis 
R. Maarten Egeler, MD, P m ,  Joseph P. Neglia, MD, MPH, Maurizio Arico, MD, 
Blaise E. Favara, MD, Andreas Heitger, MD, and Mark E. Nesbit, MD 
Langerhans cell histiocytosis (LCH) and 
malignancy occurring in  the same individual 
i s  unusual and has generally been the sub- 
ject of isolated case reports. To better define 
the occurrence of these events a registry of 
cases with synchronous or asynchronous 
LCH and malignancywas developed with the 
cooperation of the Histiocyte Society. 
In  1991 the Histiocyte Society surveyed i ts  
members requesting information on cases 
in which LCH was associated with malig- 
nancy. The questionnaire was mailed to all 
members of the society and specifically re- 
quested information on the clinical and lab- 
oratory features of the cases, disease evolu- 
tion, and response to therapy. Retrospective 
reporting was allowed. With this initial data, 
an ongoing registry of LCH patients with as- 
sociated malignancy was begun of such 
cases, including evolution and response to 
therapy. 
Twenty-seven patients were enrolled dur- 
ing the first year of the registry, of whom 4 
patients had the association of LCH with a 
malignant lymphoma and 10 cases had an 
association of LCH with other types of solid 
tumor. The remaining 13 patients had the 
association of LCH with acute leukemia. In 
five cases, LCH was associated with acute 
lymphoblastic leukemia FAB L1 (ALL). In four 
cases the ALL preceded the LCH by 6 months 
to 1 year. In four of five patients the LCH was 
localized; in two instances the LCH was 
treated with chemotherapy. In all cases the 
leukemia was treated according to local 
standard ALL protocols and in  one case au- 
tologous bone marrow transplantation 
(ABMT) was performed at relapse. Three pa- 
tients are free of leukemia, one of whom has 
persistent localized LCH of the skin. Two 
patients died of the ALL, one of whom was 
free of the LCH at the time of death. In  eight 
instances LCH was reported in association 
with acute myeloid leukemia (AML). Six of 
these patients had a generalized form of 
LCH. In seven the diagnosis of LCH pre- 
ceded the diagnosis of leukemia by more 
than 2 years (median 4 years). In the remain- 
ing patient both diagnoses were made con- 
currently. In all seven cases in  whom LCH 
was the initial diagnosis the treatment con- 
sisted of chemotherapy and/or radiother- 
apy. Seven patients died from the AML, five 
without evidence of LCH. 
The temporal patterns of the LCH-ALL and 
LCH-AML associations are distinct with ALL 
usually preceding the diagnosis of LCH and 
AML succeeding it. Such a pattern i s  sugges- 
tive that in cases of ALL the LCH may be a 
reactive process while in cases of AML oc- 
curring after LCH the primary LCH therapy 
may play an inductive role in the leukemia. 
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INTRODUCTION 
A recent review has suggested that Langerhans cell 
histiocytosis (LCH) and malignant neoplasms may occur 
in the same individual in a frequency in excess of that 
expected by chance alone [l]. In this review, the most 
common associations seen were those of LCH/lymphoma 
and LCH/solid tumors, however 24% of the cases re- 
ported were of LCH occurring either before, after, or 
coincident with the diagnosis of acute leukemia. The 
occurrence of two unusual events in a single individual 
may provide an opportunity to better understand the etiol- 
ogy or pathogenesis of one or both disorders. To facilitate 
this an ongoing registry of patients in whom LCH and a 
0 1994 Wiley-Liss, Inc. 
malignancy occurred was initiated in 1991. The follow- 
ing report summarizes the first findings of the LCH- 
Malignancy Registry. 
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METHODS 
In October 1991 all members of the Histiocyte Society 
were mailed a questionnaire requesting them to submit 
data on any patient they were currently, or had previously 
encountered, with LCH and malignancy occurring in any 
temporal sequence. The questionnaire requested the clin- 
ical, pathological, and therapeutical data of such patients. 
Additionally, selected authors of manuscripts or abstracts 
describing these associations received the questionnaire 
requesting information. Retrospective reporting was al- 
lowed. Records from each case reported to the registry 
were reviewed to confirm the diagnosis of LCH by mor- 
phologic criteria of either a CDla positive phenotype 
and/or Birbeck granules evident on electron microscopy 
P I .  
RESULTS 
Between October 1991 and October 1992, 27 cases 
who were diagnosed with LCH in association with a 
malignancy were enrolled in the registry. Thirteen of the 
27 cases had LCH associated with acute leukemia. Four 
cases had LCH and a malignant lymphoma and 10 cases 
had LCH and another type of solid tumor. 
Among the 13 cases of LCH/leukemia, there were 5 
cases of acute lymphoblastic leukemia (ALL) and 8 cases 
of LCH in association with acute myeloid leukemia 
(AML). Six cases (two ALL, four AML) were diagnosed 
at centers in North America. The remaining seven cases 
(three ALL, four AML) were enrolled from European 
centers. 
LCH and ALL 
In four of the five patients in this group the LCH was 
localized to either skin (1) or bone (3) only (Table I). The 
fifth case showed disseminated disease with involvement 
of lymph nodes, bone marrow, lungs, and liver. This 
patient and one with localized bone involvement were 
treated with chemotherapy. In the remaining patients 
with localized LCH “the therapy” consisted of a bone 
biopsy only (in the two localized bone cases) and electron 
beam irradiation (in the solitary skin involvement). In all 
but one instance the diagnosis of ALL preceded the diag- 
nosis of LCH from by 6 to 12 months, with the LCH 
occurring while the patients were under active therapy. In 
the fifth patient the ALL developed 5.5 years after the 
LCH (in this case the LCH was treated with biopsy 
alone). The ALL in all five patients was classified as 
FAB L1 and only one patient showed cytogenetic abnor- 
malities, a 9p deletion. The age of the cases varied from 
3.5 years to 9 years (median 6 years) at the time LCH was 
diagnosed. 
The ALL was in all cases treated according to local 
standard protocols and one patient who relapsed under- 
went autologous bone marrow transplantation (ABMT). 
Three patients are in remission from their leukemia. One 
of these continues to have active, localized LCH of the 
skin. The remaining two patients died of ALL, of which 
one was free of the LCH. 
LCH and AM1 
Of the eight cases in which LCH was associated with 
AML, two patients had LCH localized to bone. The re- 
maining six patients had a disseminated form of LCH 
with skin lesions in association with visceral organ in- 
volvement (4) and/or bone involvement (4) (Table I). All 
the cases with organ involvement showed organ dysfunc- 
tion of bone marrow and/or liver and/or lungs. 
The FAB classification of the AML did not show a 
specific pattern as M1, M4, and M5 were found in two 
cases each and M2 and M3 was established once. In one 
case the diagnoses of LCH and AML were made concur- 
rently. In the remaining seven patients the diagnosis of 
LCH preceded the diagnosis of leukemia by more than 2 
years (median 4 years). The age in this group varied from 
3 months to 79 years, with a median of 7.5 years. In all 
the seven patients in whom LCH was the initial diagnosis 
the treatment consisted of chemotherapy and/or radio- 
therapy for 1-6 years (Table 11). Cytogenetic abnormali- 
ties were found in four of the six cases studied. Only one 
patient remains alive, 7 months after ABMT. Of the 
seven patients who died from the AML, five did not show 
any sign of LCH. 
DISCUSSION 
Twenty-seven cases of malignancy and LCH occur- 
ring in the same individual were reported to our registry 
during its initial year. In 13 of these, the associated ma- 
lignancy was either ALL (five cases) or AML (eight 
cases). In reviewing these cases two distinct patterns of 
association appear evident; ALL preceding LCH, and 
LCH preceding AML. 
The association of LCH following a diagnosis of ALL 
(in four out of the five cases) suggests a reactive process, 
a pregenetic predisposition of ALL and LCH, and/or a 
different clinical manifestation of the same disorder. As 
all of the cases were actively undergoing ALL therapy at 
the time of the LCH diagnosis it would seem plausible 
that the ALL therapy in some way played a role in the 
expression of the LCH. Since most children with ALL 
enter remission rapidly and show no evidence of leuke- 
mia during therapy, a reaction to the malignant process 
seems unlikely. Rather, it may be that there is a predispo- 
sition of patients with ALL to LCH, and that one or more 
of the treatments given to children with ALL act as a 
co-factor, possibly through immunosuppression. In the 
one case in which the diagnosis of LCH preceded that of 
ALL the LCH was localized to bone and was “treated’ 
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TABLE 11. The Treatment in the Seven Patients With LCH in Whom the Associated AML Developed After Initial Therapy 
Patients 
1 .  
2. 
3 .  
4. 
5. 
6. 
7 .  
Chemotherapy 
vincristine Methotrexate Cyclofosfamide Chlorambucil (+ total dose, mg/m2) 
Vinblastine/ VP- 16/VM-26 
X (8,400) 
X X (4,800) 
X X X X (13,500) 
X X X x (5,000) 
X X 
X 
Radiotherapy 
X 
X 
X 
with a bone biopsy only. The ALL in this child occurred 
over 5 years later and may have been a chance occur- 
rence. 
Conversely, in eight cases in which there was the 
association of LCH and AML the diagnosis of LCH pre- 
ceded that of AML in all but one, and in all of these 
instances the LCH was treated with chemotherapy alone 
(four cases), radiation alone (one case), or both modali- 
ties (two cases). In these seven cases the temporal se- 
quence and the interval between the initial therapeutic 
exposure and the development of AML are most consis- 
tent with a therapy-related leukemia. Alternately, it could 
be speculated that the initial diagnosis of LCH was incor- 
rect, however, this seems unlikely since the cases that 
lacked a definitive diagnosis were specifically reviewed 
by their local pathologist to eliminate such a possibility. 
The morphologic characteristics of the AML were heter- 
ogenous. Three of the four cases showed cytogenetic 
abnormalities which are known to exist by secondary 
leukemia. None showed the 1 1q23 translocation charac- 
teristic of the epipodophyllotoxin-associated AML. An 
analogous situation appears to exist for the broader cate- 
gory of LCH and malignancy. 
In our previous review of 91 reported cases of LCH 
and malignancy [ 11, 39 had LCH with malignant lympho- 
mas and in 12 the LCH was associated with lung carcino- 
mas. The intimate and simultaneous association of LCH 
with malignant lymphoma and lung carcinomas sug- 
gested strongly that the process that led to this specific 
association was a reactive one. In the remaining 18 cases 
of LCH in association with a variety of other solid tu- 
mors, the LCH preceded the solid tumor 16 times, with 
69% (1 1/16) of the malignant diseases developing in the 
radiation field used for the treatment of the LCH. Simi- 
larly, in the 22 cases in which LCH was reported in 
association with leukemia, 16 (73%) were AML. In 64% 
(14 cases) the diagnosis of LCH preceded the diagnosis of 
leukemia, and it was concluded that because of the la- 
tency of the leukemia following the diagnosis of LCH, it 
was suggestive of a therapy-related process. 
LCH may present a variety of clinical situations, rang- 
ing from a solitary lesion of bone to a multisystem, life- 
threatening disorder. The clinical course of localized dis- 
ease of bone is generally benign, tends not to recur 
locally, and is not influenced greatly by any form of 
treatment. Because of the progressive nature of general- 
ized LCH, many patients have been treated with systemic 
chemotherapeutic agents. Beneficial results have been 
reported with several chemotherapeutic agents, including 
corticosteroids, vincristine, vinblastine, methotrexate, 
cyclophosphamide, chlorambucil, nitrogen mustard, cy- 
tosine-arabinoside, 6-mercaptopurine, daunorubicin, and 
etoposide [3]. Several studies have reported the use of 
cornbination chemotherapy. Although the development 
of chemotherapy has improved survival considerably in 
children with cancer, this is not as dramatic for general- 
ized LCH. 
The LCH-AML cases reported here and previously 
raise concern about the induction of leukemia by LCH 
therapy. There have been extensive reports of survivors 
of pediatric malignancies who developed secondary 
AML after successful treatment with alkylating agents 
[4,5], epipodophyllotoxin [6,7], and radiotherapy [8]. 
Epipodophyllotoxins, however, have been shown to be 
very effective in disseminated LCH [9,10]. The risk of 
secondary AML for this drug appears to be related to the 
total dose and the schedule of administration [6,7]. Fur- 
thermore, in most if not all reports, VP-16/VM-26 is given 
in combination with other chemotherapeutics. In the 
cases who were enrolled in the registry, just one was 
treated with VP-16 as single agent and in most cases the 
treatment was given for a very long time with a high total 
dose. 
It is imperative however to remember that patients 
with disseminated LCH, especially those with organ dys- 
function at the time of diagnosis, are expected to have 
only a 45-50% probability of surviving for 5 years [ 1 11. 
Although complications for some of the more hazardous 
types of therapies are well known, the most effective and 
safe treatment for LCH has not yet been established. Only 
cooperative large scale clinical studies will be able to 
provide insight into the role of chemotherapy in this dis- 
order and the risWbenefit ratio associated with therapy. 
Continuing registration of LCH patients with malignant 
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